| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net gain on realized contingent milestone and royalty assets | - | 75,137 | - | - |
| Income (loss) before income taxes | -2,889 | 73,206 | -14,138 | -10,052 |
| Provision for income tax benefit (expense) | -6,504 | 18,371 | -559 | 2,646 |
| Net income (loss) | 3,615 | 54,835 | -13,579 | -12,698 |
| Net unrealized gain on available-for-sale investments | 42 | -10 | -7 | 72 |
| Total comprehensive income (loss) | 3,657 | 54,825 | -13,586 | -12,626 |
| Earnings per share, basic | 0.07 | 1.09 | -0.27 | -0.26 |
| Earnings per share, diluted | 0.07 | 1.08 | -0.27 | -0.26 |
| Weighted average number of shares outstanding, basic | 50,520,000 | 50,177,000 | 49,706,000 | 49,038,000 |
| Weighted average number of shares outstanding, diluted | 51,908,000 | 50,726,000 | 49,706,000 | 49,038,000 |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)